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The original bicyclam, JM1657 (JM stand-
ing for Johnson Matthey) was discovered as
a contaminant in a commercial preparation
of monocyclams when evaluated for their
anti-HIV activity. The original compound,
in which the cyclam rings were tethered by
a C–C linkage could not be re-synthesized
but launched the synthesis of new bicy-
clams in which the cyclam moieties were
linked through an aliphatic bridge: one of
these derivatives, i.e., JM2763, exhibited an
anti-HIV activity similar to that of JM1657
(1). The compound was postulated to
FIGURE 1 | (A) Structure of AMD3100. (B) Inhibitory effect of
AMD3100 on Ca++ flux in CXCR4 transfected cells (9). (C)The CXCR4
receptor. Crucial aspartic acid residues at positions 171, 182, 193, and
262 in the interaction of CXCR4 with AMD3100 are indicated (11).
(D) Mobilization of CD34+ hematopoietic stem cells (HSCs) by
AMD3100 (12).
interfere with the uncoating of HIV, a stage
in the replicative cycle of HIV, which was
(and still is) ill-defined. A quantum jump
in anti-HIV potency was achieved with
the synthesis of AMD3100 (AMD standing
for AnorMeD) (which was originally called
JM3100), where the two cyclam rings are
tethered by an aromatic bridge (Figure 1A)
(2). The compound was active against HIV
in the low nanomolar concentration range
and generated considerable commercial
interest, although its precise mechanism of
action remained enigmatic (3, 4). Finally,
the viral glycoprotein gp120 was identified
as the molecular target of AMD3100 (5).
It appeared to be an indirect target. The
direct target was CXCR4, with which gp120
has to interact for HIV to enter the cells.
AMD3100 was shown to specifically antag-
onize CXCR4, and thus to block the entry
of the T-lymphotropic HIV strains (6–8).
AMD3100 appears to be a highly specific
inhibitor of CXCR4 (9): it only blocks, as
measured by the Ca++ flux, the signal path-
way from CXCR4 (Figure 1B) and not that
of any other receptor for either CXC- or
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C–C-chemokines (9). Certain aspartic acid
residues play an essential role in the interac-
tion of CXCR4 with AMD3100 (Figure 1C)
(10, 11).
Within the scope of the potential clin-
ical use of AMD3100 for the treatment
of HIV infections, initial phase 1 clini-
cal trials were initiated (13). These studies
revealed an increase in the white blood
cell (WBC) counts peaking at about 8–
10 h after (subcutaneous) injection. These
WBCs contained hematopoietic stem cells
(HSCs) carrying the CD34 marker (12)
(Figure 1D). In fact, the first proof-of-
principle that AMD3100 could mobilize
hematopoietic stem and progenitor cells
was provided by Broxmeyer et al. (14).
Thus, the concept was born that AMD3100
(now also called plerixafor or Mozobil®)
could function as a mobilizer of HSCs. This
mobilization is clearly based on the interac-
tion of AMD3100 with CXCR4. CXCR4 is
normally the receptor for the chemokine
SDF-1 (now called CXCL12), which is
responsible for the “homing” of the HSCs
in the bone marrow. Under the influence
of AMD3100, the HSCs leave the bone
marrow to enter the bloodstream where
they can be collected and subsequently
used for autologous transplantation. In
December 2008, Mozobil® was approved
by the FDA for this indication in patients
with non-Hodgkin’s lymphoma or multi-
ple myeloma. It is used in combination
with granulocyte-colony stimulating factor
(G-CSF) [for review, see Keating (15)]. For
prescribing information, see Ref. (16).
AMD3100 was not further developed
for the treatment of HIV infections
essentially because of two reasons: (i)
AMD3100 was not effective against the
M-tropic CCR5 HIV strains, a problem
that could be circumvented by the con-
comitant (oral) use of a CCR5 antago-
nist, maraviroc (Selzentry®), and (ii) it
had to be injected subcutaneously, as it
was not orally bioavailable. Subcutaneous
injection is indeed a problem for long-
term administration, and Fuzeon® (enfu-
virtide) is the only anti-HIV drug out of
more than 25, which has to be administered
by injection, and, therefore, not widely
used. Attempts to increase the spectrum
of AMD3100 derivatives toward M-tropic
HIV strains and, particularly, to increase
their oral bioavailability led to the syn-
thesis of AMD3465 (17), AMD11070 (18),
and various other compounds (19–21),
which, however, were not further devel-
oped as clinical candidates for treatment
of HIV infections. Related CXCR4 antag-
onists such as KRH-1636 (22), KRH-3955
(23), and T140 analogs (24) were described
by Naoki Yamamoto and his colleagues in
Japan.
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